Aspyrian Therapeutics, Inc. logo

Aspyrian Therapeutics, Inc.

Aspyrian Therapeutics is an healthcare, pharmaceuticals and biotech industry. Aspyrian Therapeutics s developing novel cancer targeted therapies based on its proprietary Photoimmunotherapy (PIT) platform, which achieve highly specific and tumor restricted anticancer activity.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://rakutenaspyrian.com
Disease Focus
STOCK CODENon Listed
Address
11080 Roselle Street, CA 92121
San Diego
United States
Email
Contact Number
+1 8584494339

Aspyrian Therapeutics s developing novel cancer targeted therapies based on its proprietary Photoimmunotherapy (PIT) platform, which achieve highly specific and tumor restricted anticancer activity.

Aspyrian secured an exclusive license for Antibody Conjugate Technology: Near-infrared Photoimmunotherapy (PIT) developed at the National Cancer Institute (NCI) by Hisataka Kobayashi and Peter Choyke, under the NCIs molecular imaging program.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/rakuten-aspyrian” connections=”true” suffix=””]

Near-infrared Photoimmunotherapy (PIT) is based on three components: 1. An antibody that binds to cell-surface antigens.
2. The NIR IR700DX dye conjugated to the antibody via a stable linkage.
3. NIR light dosimetry to activate the conjugate (cell killing occurs whether the conjugate is surface-bound or internalized).

Pipeline

RM-1929 is an antibody Cetuximab conjugate with a non-toxic payload (IRDyeë 700DX) that precisely targets specific cancer antigen allowing treatment of a number of different cancer types, including cancers of the head and neck, esophagus, lung, colon, and pancreas.

RM-1929 is administered systemically but its pharmacological action is limited to the tumors where laser mediated activation triggers cancer cell killing resulting in rapid, robust, and highly specific anticancer responses.

FDA grants Fast Track designation for RM-1929 to treat recurrent Head and Neck cancer patients that have failed two lines of therapy.

In March 2014, Aspyrian signed agreement with Goodwin Biotechnology for the technology transfer, process development, scale-up, and cGMP manufacturing of a novel Antibody Drug Conjugate (ADC) for use in Phase I clinical trials.

In July 2017, Aspyrian raised $19 Mn as part of a Series B-1 financing round. Earlier in Mar 2016, Aspyrian closed a $40 Mn Series B financing. The Series B financing was provided by Hiroshi Mikitani, CEO of Rakuten, Inc., one of the worlds leading internet e-commerce and service companies headquartered in Japan. Also in Jan 2015, Aspyrian raised almost $8.5 Mn from an undisclosed investors.